These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 2513156)

  • 1. Value of post-therapy whole-body I-131 imaging in the evaluation of patients with thyroid carcinoma having undergone high-dose I-131 therapy.
    Spies WG; Wojtowicz CH; Spies SM; Shah AY; Zimmer AM
    Clin Nucl Med; 1989 Nov; 14(11):793-800. PubMed ID: 2513156
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Value of thyroid carcinoma imaging after therapeutic doses of radioiodine.
    Balachandran S; Sayle BA
    Clin Nucl Med; 1981 Apr; 6(4):162-7. PubMed ID: 7214771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. I-123 whole body scanning: case report and discussion.
    Klein HA; DiSibio KJ; Sims D; Singleton HC; Worthy LJ
    Clin Nucl Med; 2005 May; 30(5):312-6. PubMed ID: 15827398
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sensitivity of 123I whole-body scan and thyroglobulin in the detection of metastases or recurrent differentiated thyroid cancer.
    de Geus-Oei LF; Oei HY; Hennemann G; Krenning EP
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):768-74. PubMed ID: 12029550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Iodine-131 treatment of thyroid cancer: absorbed dose calculated from post-therapy scans.
    Koral KF; Adler RS; Carey JE; Beierwaltes WH
    J Nucl Med; 1986 Jul; 27(7):1207-11. PubMed ID: 3723194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 131I therapeutic efficacy is not influenced by stunning after diagnostic whole-body scanning.
    Dam HQ; Kim SM; Lin HC; Intenzo CM
    Radiology; 2004 Aug; 232(2):527-33. PubMed ID: 15286323
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radioiodine therapy for differentiated thyroid carcinoma.
    Connor CS; Thomas JH; Robinson RG; Preston DF; Hermreck AS
    Am J Surg; 1988 Dec; 156(6):519-21. PubMed ID: 3202264
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differentiated thyroid carcinoma: Incremental diagnostic value of
    Zilioli V; Peli A; Panarotto MB; Magri G; Alkraisheh A; Wiefels C; Rodella C; Giubbini R
    Endocrine; 2017 Jun; 56(3):551-559. PubMed ID: 27709475
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Stunning with 131I diagnostic whole-body imaging of patients with thyroid cancer.
    Gerard SK; Dam HQ
    Radiology; 2005 Mar; 234(3):972-3; author reply 973-4. PubMed ID: 15734947
    [No Abstract]   [Full Text] [Related]  

  • 10. Can iodine-131 whole-body scan be replaced by thyroglobulin measurement in the post-surgical follow-up of differentiated thyroid carcinoma?
    Ronga G; Fiorentino A; Paserio E; Signore A; Todino V; Tummarello MA; Filesi M; Baschieri I
    J Nucl Med; 1990 Nov; 31(11):1766-71. PubMed ID: 2121913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of low-dose iodine-131 ablation of post-operative thyroid remnants: a study of 69 cases.
    Leung SF; Law MW; Ho SK
    Br J Radiol; 1992 Oct; 65(778):905-9. PubMed ID: 1422665
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic value of the 131I whole-body scan in postsurgical therapy for differentiated thyroid cancer.
    Pupi A; Castagnoli A; Morotti A; La Cava G; Meldolesi U
    Cancer; 1983 Aug; 52(3):439-41. PubMed ID: 6407747
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insensitivity of Tc-99m pertechnetate for detecting metastases of differentiated thyroid carcinoma.
    Campbell CM; Khafagi FA
    Clin Nucl Med; 1990 Jan; 15(1):1-4. PubMed ID: 2155079
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of low-dose radioiodine ablation therapy in postsurgical thyroid cancer patients.
    Ramanna L; Waxman AD; Brachman MB; Tanasescu DE; Sensel N; Braunstein GD
    Clin Nucl Med; 1985 Nov; 10(11):791-5. PubMed ID: 4075672
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complementary role of whole body scan and serum thyroglobulin determination in the follow-up of differentiated thyroid carcinoma.
    Ronga G; Fiorentino A; Fragasso G; Fringuelli FM; Todino V
    Ital J Surg Sci; 1986; 16(1):11-5. PubMed ID: 3087907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Visualization of the thymus with therapeutic doses of radioiodine in patients with thyroid cancer.
    Michigishi T; Mizukami Y; Shuke N; Yokoyama K; Noguchi M; Watanabe Y; Matsui O; Aburano T; Tonami N; Hisada K
    Eur J Nucl Med; 1993 Jan; 20(1):75-9. PubMed ID: 8267685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up regimen of differentiated thyroid carcinoma in thyroidectomized patients after thyroid hormone withdrawal.
    Oyen WJ; Verhagen C; Saris E; van den Broek WJ; Pieters GF; Corsten FH
    J Nucl Med; 2000 Apr; 41(4):643-6. PubMed ID: 10768565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The significance of 1-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication.
    Waxman A; Ramanna L; Chapman N; Chapman D; Brachman M; Tanasescu D; Berman D; Catz B; Braunstein G
    J Nucl Med; 1981 Oct; 22(10):861-5. PubMed ID: 7288483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Partial stunning in thyroid remnant after administration of scanning dose followed by 100 mCi I-131 therapy.
    Yagcloglu H; Ozalp E; Ibis E; Aras G
    Clin Nucl Med; 1996 Apr; 21(4):340. PubMed ID: 8925630
    [No Abstract]   [Full Text] [Related]  

  • 20. Self-stunning in thyroid ablation: evidence from comparative studies of diagnostic 131I and 123I.
    Hilditch TE; Dempsey MF; Bolster AA; McMenemin RM; Reed NS
    Eur J Nucl Med Mol Imaging; 2002 Jun; 29(6):783-8. PubMed ID: 12029552
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.